Proteases as tools for diagnosis and novel therapeutics

S. Meiners (München, Germany)

Source: ERS Research Seminar 2015

Number: 5

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Meiners (München, Germany). Proteases as tools for diagnosis and novel therapeutics. ERS Research Seminar 2015

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Novel targets and emerging therapies in MPM Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019
Novel therapeutics for CF Source: International Congress 2019 – Future of cystic fibrosis care: insights from the Lancet Commission Year: 2019
From anti-PD1/L1 inhibitors to new immunotherapies Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
Clinical implications and novel therapies Source: International Congress 2018 – Accelerated ageing in lungs Year: 2018
Novel NTM treatments and approaches, repurposed to bacteriophages Source: Virtual Congress 2021 – New insights into nontuberculous mycobacteria disease: from diagnosis to treatment Year: 2021
Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19 Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020 Year: 2020
Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008
COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007
COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020 Year: 2020
Classic and Novel Adipokines as diagnostic biomarkers in NSCLC Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019
Genomics-based identification of targets in pathogenic bacteria for potential therapeutic use Source: Annual Congress 2004 - Novel approaches to the treatment of pneumonia Year: 2004
Bronchiectasis: state-of-the-art diagnostic and therapeutic approaches Source: Virtual Congress 2021 – Respiratory infections Year: 2021
Genetic studies as a tool for identifying novel potential targets for treatment of COPD Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017 Year: 2017
Targeting the arginase pathway: potential developments as new avenues for treatment Source: Annual Congress 2004 - Arginase: a novel target and marker for asthma? Year: 2004
The genetics of asthma and the promise of genomics-guided drug discovery Source: Virtual Congress 2020 – Reducing the burden of asthma Year: 2020
COPD – will new insights into molecular pathology define new therapies? Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014
Potential of regulatory T-cell-based therapies in the management of severe COVID-19 Source: Eur Respir J, 56 (3) 2002182; 10.1183/13993003.02182-2020 Year: 2020